Quantbot Technologies LP increased its holdings in shares of Array BioPharma Inc. (NASDAQ:ARRY) by 803.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,205 shares of the biopharmaceutical company’s stock after purchasing an additional 16,190 shares during the quarter. Quantbot Technologies LP’s holdings in Array BioPharma were worth $223,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Teacher Retirement System of Texas increased its position in shares of Array BioPharma by 8.3% during the 2nd quarter. Teacher Retirement System of Texas now owns 12,737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 972 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Array BioPharma during the 2nd quarter valued at approximately $110,000. Ameritas Investment Partners Inc. increased its position in shares of Array BioPharma by 7.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 15,148 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 1,012 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Array BioPharma during the 3rd quarter valued at approximately $146,000. Finally, Raymond James Financial Services Advisors Inc. increased its position in shares of Array BioPharma by 71.9% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 18,317 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 7,661 shares during the last quarter. 98.24% of the stock is owned by institutional investors.

In other Array BioPharma news, Director Kyle Lefkoff sold 38,865 shares of the firm’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $12.31, for a total transaction of $478,428.15. Following the completion of the transaction, the director now owns 51,585 shares of the company’s stock, valued at $635,011.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.18% of the company’s stock.

Array BioPharma Inc. (ARRY) opened at $11.25 on Friday. Array BioPharma Inc. has a 12-month low of $6.73 and a 12-month high of $13.40. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.43 and a quick ratio of 5.43.

Array BioPharma (NASDAQ:ARRY) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.22). Array BioPharma had a negative net margin of 89.30% and a negative return on equity of 158.70%. The company had revenue of $29.75 million for the quarter, compared to analysts’ expectations of $33.74 million. During the same period in the prior year, the business earned ($0.20) earnings per share. Array BioPharma’s revenue for the quarter was down 24.2% compared to the same quarter last year. equities research analysts expect that Array BioPharma Inc. will post -0.99 EPS for the current year.

ARRY has been the subject of a number of recent analyst reports. J P Morgan Chase & Co restated a “buy” rating and set a $14.00 price objective on shares of Array BioPharma in a report on Monday, September 11th. Cantor Fitzgerald set a $15.00 target price on Array BioPharma and gave the company a “buy” rating in a report on Tuesday, October 31st. Jefferies Group restated a “buy” rating and issued a $9.00 price target on shares of Array BioPharma in a research report on Tuesday, September 12th. Stifel Nicolaus restated a “buy” rating on shares of Array BioPharma in a research report on Wednesday, November 1st. Finally, SunTrust Banks reiterated a “buy” rating and set a $16.00 target price on shares of Array BioPharma in a research report on Wednesday, November 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $13.65.

WARNING: “Array BioPharma Inc. (ARRY) Shares Bought by Quantbot Technologies LP” was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/12/01/array-biopharma-inc-arry-shares-bought-by-quantbot-technologies-lp.html.

About Array BioPharma

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Want to see what other hedge funds are holding ARRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Array BioPharma Inc. (NASDAQ:ARRY).

Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)

Receive News & Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.